Overview
NICE is unable to make a recommendation about the use in the NHS of bosutinib (Bosulif) for untreated chronic myeloid leukaemia in adults because no evidence submission was received from Pfizer.
Last reviewed: 17 April 2019
Next review: We will review this decision if the company decides to make a submission.